Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy.

about

Nonspreading Rift Valley Fever Virus Infection of Human Dendritic Cells Results in Downregulation of CD83 and Full Maturation of Bystander Cells.

P2860

Q40130716-88A909A1-0A96-4352-A829-0493FA39F61A

P2860

Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy.

Item

http://www.wikidata.org/entity/Q40151111

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy.

@en

type

Item

label

Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy.

@en

prefLabel

Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy.

@en

P1476

Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy.

@en

P2093

J Kortekaas

http://www.w3.org/2001/XMLSchema#string

L Spel

http://www.w3.org/2001/XMLSchema#string

P J Wichgers Schreur

http://www.w3.org/2001/XMLSchema#string

R J M Moormann

http://www.w3.org/2001/XMLSchema#string

R P M Vloet

http://www.w3.org/2001/XMLSchema#string

P2860

Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus.

Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity.

A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells.

An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer

A single vaccination with an improved nonspreading Rift Valley fever virus vaccine provides sterile immunity in lambs.

Creation of a nonspreading Rift Valley fever virus

RNA helicase signaling is critical for type i interferon production and protection against Rift Valley fever virus during mucosal challenge.

Evaluation of nonspreading Rift Valley fever virus as a vaccine vector using influenza virus hemagglutinin as a model antigen.

Comparative efficacy of two next-generation Rift Valley fever vaccines.

Efficacy of three candidate Rift Valley fever vaccines in sheep.

P304

9124-9127

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.01105-15

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marianne Boes

N Oreshkova

P577

2015-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26085169

http://www.w3.org/2001/XMLSchema#string

P921

P932

4524072

http://www.w3.org/2001/XMLSchema#string

Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy.

about

P2860

P2860

Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932